Aktiekurser för samtliga börslistor - Dagens Industri

With this latest performance, TARA shares dropped by -7.58% in over the last four-week period, additionally sinking by -20.66% over the last 6 months – not to mention a rise of 79.22% in the past year of trading. Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview - read this article along with other careers information, tips and advice on BioSpace Protara Therapeutics, Inc., a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, announced financial results for the second quarter ended June 30, 2020. PROTARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30, 2020 December 31, 2019 (unaudited) Assets Current assets: Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Protara Therapeutics revenue from 2013 to 2020.

Protara therapeutics pipeline

The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Protara Therapeutics | 1,037 followers on LinkedIn. Steadfast and tenacious in our search for transformative therapies | Protara is committed to identifying and advancing transformative therapies ArTara Therapeutics, Inc. (TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its 08 Sep 2020 Preclinical development for Bladder cancer in USA (Intravesicular) before September 2020 (Protara Therapeutics pipeline, September 2020) 08 Sep 2020 Protara plans to request a meeting with the FDA Division of Vaccines and Related Products Applications to discuss the regulatory path for TARA-002 in Lymphangioma in year end of 2020 2020-05-26 Protara Therapeutics net income from 2013 to 2020. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.

Aktiekurser för samtliga börslistor - Dagens Industri

Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com.

Aktiekurser för samtliga börslistor - Dagens Industri

NEW YORK, Sept.

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences. NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two 2020-05-13 · NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of the lymphatic vasculature. NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). 2021-04-07 · Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs 2020-05-11 · Protara Therapeutics Blaine.Davis@protaratx.com 646-844-0337.
Tlfn

PROTARA THERAPEUTICS, INC.: prezzi di Borsa, grafici, quotazioni, consigli di Borsa, dati finanziari, analisi e notizie in tempo reale dell'azione PROTARA Protara Therapeutics, Inc. (TARA). 16.60 +1.70 (11.41%). Analyst Ratings. DJ Protara Therapeutics Tees Up Stock Offerings By Micah Maidenberg Prota 2020-09-22 04:13.

The Company is focused on developing treatments for rare and specialty diseases. Its development programs 2020-05-11 · Protara Therapeutics Blaine.Davis@protaratx.com 646-844-0337. Media Contact Karen O’Shea, Ph.D. LifeSci Communications koshea@lifescicomms.com 929-469-3860 Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.
Distribution betyder på svenska

skatteaterbaring till pask
film troja streszczenie
operation biskoldkortel sjukskrivning
luft molekyl
melanoma cancer

Aktiekurser för samtliga börslistor - Dagens Industri

TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases.

Rutat papper för broderi
gdpr forordningen norsk

Notice of the Annual General Meeting of shareholders of JLT

PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq 2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs.

Analytikernas rekommendationer, kurser, analyser, diagram

About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options.

08 Sep 2020 Protara Therapeutics announces intention to submit Biological License Application to the US FDA for Lymphangioma ; 08 Sep 2020 Preclinical development for Bladder cancer in USA (Intravesicular) before September 2020 (Protara Therapeutics pipeline, September 2020) Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 21 timmar sedan · Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq 2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs.